Tilbake til siden "Om Brystkreft"

 

 

 

Referanser

  • Cancer Registry of Norway. Cancer in Norway 2017 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. 2018.
  • Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941-53.
  • Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft. 2019;IS-2831.
  • Kreftregisteret. Årsrapport 2017 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft. Oslo: Kreftregisteret. 2018.
  • Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. 2011;365(14):1273-83.
  • Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Annals of Oncology. 2012;23(suppl_6):vi7-vi12.
  • Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. New England Journal of Medicine. 2010;363(20):1938-48.
  • Waks AG, Winer EP. Breast Cancer Treatment: A Review JAMA. 2019;321(3):288-300.

 

NO/BREAST/1908/0004